Evidence-Based Diabetes Management JDRF's Kowalski Sees Hope in Bipartisan Support for Insulin Pricing Reform
September 26, 2019
By Andrew Smith
Aaron Kowalski, PhD, the new CEO of the JDRF, says in a discussion about insulin pricing that action is needed not only by Congress, but also by insulin makers, health plans, and the executive branch. The most important goal: ending a crosspayment scheme that many blame for potentially deadly price increases.